SUCCINYLCHOLINE CHLORIDE- succinylcholine chloride injection Renaissance Lakewood LLC

Succinylcholine Chloride Injection USP, 20 mg/mL

WARNING

RISK OF CARDIAC ARREST FROM HYPERKALEMIC RHABDOMYOLYSIS


There have been rare reports of acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest and death after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne's muscular dystrophy.

This syndrome often presents as peaked T-waves and sudden cardiac arrest within minutes after the administration of the drug in healthy appearing pediatric patients (usually, but not exclusively, males, and most frequently 8 years of age or younger). There have also been reports in adolescents.

Therefore, when a healthy appearing infant or child develops cardiac arrest soon after administration of succinylcholine, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. This should include administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation. Due to the abrupt onset of this syndrome, routine resuscitative measures are likely to be unsuccessful. However, extraordinary and prolonged resuscitative efforts have resulted in successful resuscitation in some reported cases. In addition, in the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.

Since there may be no signs or symptoms to alert the practitioner to which patients are at risk, it is recommended that the use of succinylcholine in pediatric patients should be reserved for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION).

Primary package for Succinylcholine



succinylcholine chloride injection

| Product Information | | | | |
|-------------------------|-------------------------|--------------------|----------------|--|
| Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:49396-0152 | |
| Route of Administration | PARENTERAL | | | |

| Active Ingredient/Active Moiety | | | |
|---|-----------------------------|--------------------|--|
| Ingredient Name | Basis of Strength | Strength | |
| SUCCINYLCHOLINE CHLORIDE (UNII: 19 L 0 DDD 30 I) (SUCCINYLCHOLINE - UNII: J2R8 6 9 A8 YF) | SUCCINYLCHOLINE CHLORIDE | 200 mg in 10 mL | |

| Inactive Ingredients | | |
|----------------------------------|----------|--|
| Ingredient Name | Strength | |
| PROPYLPARABEN (UNII: Z8IX2SC1OH) | | |

| Packaging | | | | |
|-----------|------------------|--|-----------------------------|--------------------|
| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
| 1 | NDC:49396-0152-2 | 6 in 1 BOX | 10/01/2018 | |
| 1 | | 25 in 1 CARTON | | |
| 1 | | 10 mL in 1 VIAL; Type 0: Not a Combination Product | | |

| Marketing Information | | | | |
|-----------------------|--|----------------------|--------------------|--|
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date | |
| ANDA | ANDA210231 | 10/01/2018 | | |
| | | | | |

Labeler - Renaissance Lakewood LLC (077744035)

Registrant - Renaissance Lakewood LLC (077744035)

| Establishment | | | | |
|--------------------------|---------|-----------|---|--|
| Name | Address | ID/FEI | Business Operations | |
| Renaissance Lakewood LLC | | 077744035 | manufacture(49396-0152), analysis(49396-0152) | |

Revised: 6/2018 Renaissance Lakewood LLC